NCT07676344Not yet recruiting
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
Metastatic breast cancer remains an incurable disease for most patients. While surgical treatment of the primary breast tumor is commonly performed in localized breast cancer, its role in metastatic breast cancer remains controversial due to the lack of demonstrated survival benefit and the potential interruption of systemic anticancer therapies. Cryoablation is a minimally invasive outpatient procedure that destroys tumor tissue through controlled freezing. In localized breast cancer, cryoablation has shown promising results regarding local tumor control, safety, and patient quality of life. However, evidence regarding its use in metastatic breast cancer remains limited.The primary objective of this prospective single-center cohort study is to evaluate local tumor control 12 months after cryoablation of the primary breast tumor in patients with metastatic breast cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- First submitted
- 24 Jun 2026
- Start date
- Oct 2026
- Primary completion date
- Jan 2030
- Lead sponsor
- Hospices Civils de Lyon
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07676344
What you commit to
- Study type: Interventional
- Planned participants: 42
- From Oct 2026 to the primary completion date, Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychiatric disorder or any medical condition that, in the opinion of the investigator, could compromise study participation or compliance with study procedures.
Other
- Contraindication to cryoablation according to the investigator and/or interventional radiologist.
- Contraindication to gadolinium-enhanced breast MRI according to institutional practice and radiologist assessment.
- Pregnant or breastfeeding women.
- Participation in another interventional clinical study with an ongoing exclusion period or that could interfere with the present study according to investigator judgment.
- Adults under legal protection or unable to provide informed consent.
- Persons deprived of liberty by judicial or administrative decision.
- Absence of health insurance coverage.
Who the study is looking for
- Female aged ≥18 years.
- Histologically confirmed metastatic breast carcinoma, regardless of histological subtype, hormone receptor status, HER2 status, or tumor grade.
- Receiving systemic anticancer treatment for metastatic breast cancer, including chemotherapy, immunotherapy, endocrine therapy, targeted therapy, or combination regimens.
- Clinical response or stable disease according to RECIST v1.1 on the most recent imaging assessment performed within 3 months before enrollment, except for the primary breast lesion, which may be progressing.
- Eligible for cryoablation of the primary breast tumor:
- ECOG Performance Status ≤2.
- Effective contraception for women of childbearing potential.
- Able and willing to provide written informed consent.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Lyon Sud Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.